Gram positive infection in trauma patients: new strategies to decrease emerging Gram-positive resistance and vancomycin toxicity (Q34117834)

31 July 2017

title

Gram positive infection in trauma patients: new strategies to decrease emerging Gram-positive resistance and vancomycin toxicity (English)

1 reference

31 July 2017

main subject

gram-positive bacteria

0 references

1 reference

Ginzburg E

1

1 reference

31 July 2017

Namias N

2

1 reference

31 July 2017

Brown M

3

1 reference

31 July 2017

Ball S

4

1 reference

31 July 2017

Hameed SM

5

1 reference

31 July 2017

Cohn SM

6

1 reference

31 July 2017

language of work or name

1 reference

1 November 2000

1 reference

International Journal of Antimicrobial Agents

31 July 2017

published in

1 reference

31 July 2017

volume

16 Suppl 1

1 reference

31 July 2017

page(s)

S39-42

1 reference

National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900305-8

7 January 2021

Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900305-8

7 January 2021

The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900305-8

7 January 2021

Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900305-8

7 January 2021

In vitro susceptibility patterns of methicillin-resistant and-susceptible Staphylococcus auerues strains in a population of parenteral drug abusers from 1972 to 1981.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900305-8

7 January 2021

Alternatives to vancomycin in treating methicillin-resistant Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900305-8

7 January 2021

In-vitro susceptibility of isolates of methicillin-resistant Staphylococcus aureus 1988-1993

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900305-8

7 January 2021

Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900305-8

7 January 2021

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900305-8

7 January 2021

10.1016/S0924-8579(00)00305-8

Identifiers

DOI

0 references

1 reference